28.07

2.37% -0.68

Pre-market: 29.06 0.99 +3.53%

Avalyn Pharma Inc (AVLN)

Overview News Price History Discussions Forecast

Avalyn Pharma Inc stock is traded at $28.07, with a volume of 382.45K. It is down -2.37% in the last 24 hours and down -5.93% over the past month. Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Previous Close:

$28.75

Open:

$28.26

24h Volume:

382.45K

Relative Volume:

2.82

Market Cap:

$1.24B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-2.09%

1M Performance:

-5.93%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$28.00

$29.78

1-Week Range:

$26.02

$32.19

52-Week Range:

$24.15

$32.23

Avalyn Pharma Inc Stock (AVLN) Company Profile

Name

Avalyn Pharma Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(206) 707-0340

Address

105 W FIRST ST., BOSTON

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

AVLN's Discussions on Twitter

Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVLN Avalyn Pharma Inc	28.07	1.27B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Avalyn Pharma Inc Stock (AVLN) Latest News

Jun 11, 2026

IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace

Jun 11, 2026

Jun 08, 2026

Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat

Jun 08, 2026

Jun 06, 2026

Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent

Jun 06, 2026

Jun 05, 2026

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl

Jun 05, 2026

Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛

Jun 05, 2026

Jun 04, 2026

Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart

Jun 04, 2026

Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView

Jun 03, 2026

Avalyn: Q1 Earnings Snapshot - marketscreener.com

Jun 03, 2026

AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView

Jun 03, 2026

Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan

Jun 03, 2026

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times

Jun 03, 2026

Jun 02, 2026

Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat

Jun 02, 2026

Jun 01, 2026

Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga

Jun 01, 2026

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance

Jun 01, 2026

May 30, 2026

Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat

May 30, 2026

May 29, 2026